Cannabis

Share
Print
Share
Print
Cannabis leaf

Common Names

  • Marijuana
  • Ganja
  • Bhang
  • Weed
  • Pot
  • Grass
  • Dope
  • Reefer
  • Hash
  • (>1000 other terms)

For Patients & Caregivers

Tell your healthcare providers about any dietary supplements you’re taking, such as herbs, vitamins, minerals, and natural or home remedies. This will help them manage your care and keep you safe.


What is it?

Cannabis, also known as marijuana, is used to treat some symptoms related to cancer. It’s made from the flowers, leaves, and resin (sticky chemical) of the Cannabis sativa plant.

Cannabis comes in many forms, including vape pens, pills, lozenges, oils, teas, and powder. It isn’t a prescription medication. It can be taken orally (by mouth), by smoking, or by vaporizing.

A licensed doctor or advanced practice provider (APP) must certify you if you want to buy medical marijuana from a registered dispensing facility (a place where medical marijuana is sold).

What is it used for?

Cannabis is used to:

  • Reduce pain
  • Treat glaucoma (eye disease that causes vision loss and blindness)
  • Treat nausea (feeling like you’re going to throw up) and vomiting (throwing up) due to cancer treatments
  • Treat sleep disorders
  • Treat epilepsy (a brain disorder that causes people to have seizures)
  • Treat multiple sclerosis (disease that can cause problems with vision, balance, and muscle control)
  • Treat mood disorders such as depression, bipolar disorder, and seasonal affective disorder
  • Increase appetite

Cannabis also has other uses that haven’t been studied by doctors to see if they work.

Talk with your healthcare providers before taking cannabis. It can interact with some medications and affect how they work. For more information, read the “What else do I need to know?” section below.

What are the side effects?

Side effects of taking cannabis products may include:

  • Drowsiness (feeling sleepy)
  • Restlessness (feeling like you can’t relax or get comfortable)
  • Anxiety (strong feelings of worry or fear)
  • Paranoia (intense thoughts or feelings that someone might try to harm you)
  • Hallucinations (seeing or hearing things that aren’t there)
  • Feeling hungry
  • Short-term memory loss
  • Euphoria (feeling very happy or excited)
  • Trouble focusing
  • Changes in your blood pressure
  • Faster heart rate
  • Confusion
  • Nausea (feeling like you’re going to throw up)
  • Vomiting (throwing up)
  • Flushing (when your skin becomes red or warm)
  • Depression (strong feelings of sadness)
  • Insomnia (trouble falling asleep, staying asleep, or waking up too early)

If you’re worried about any of these side effects, talk with your healthcare provider.

What else do I need to know?

Don’t take cannabis products if:

  • You have kidney, heart, or liver disease. Cannabis may make these worse.
  • You have psychiatric illnesses that affect mood, thinking, and behavior. Cannabis may make these conditions worse.
  • You’re taking nivolumab (Opdivo®). Cannabis can lower the response to this medication in patients with advanced melanoma, non-small-cell lung cancer, and renal clear cell carcinoma.
  • You’re taking warfarin (Jantoven® or Coumadin®) or other blood thinners. Cannabis can increase your risk of bleeding.
  • You’re taking fluoxetine (Prozac®) or disulfiram (Antabuse®). Taking cannabis with these medications can cause confusion, elevated mood, inflated self-esteem, decreased need for sleep, racing thoughts, and trouble focusing.
  • You’re on amphetamines (Adzenys XR-ODT, Evekeo ODT). Heart damage may occur with cannabis
  • You’re taking atropine (Atropen®). Taking this medication and cannabis can cause heart damage.
  • You’re on cocaine. Heart damage may occur with cannabis
  • You’re taking pseudoephedrine (such as Sudafed ®), epinephrine (such as Auvi-Q®) or the prescription drug dobutamine (Dobutamine). Taking these medications and cannabis can cause heart damage.
  • You’re taking medication that helps you sleep such as lorazepam (Ativan®), diazepam (Valium®), or zolpidem (Ambien®). Taking these medications and cannabis can increase drowsiness.

Don’t give cannabis products to children with epilepsy who are on clobazam (Onfi®). Cannabis can increase its side effects

Don’t use medical marijuana for anything other than managing your cancer-related symptoms. Non-medical use of cannabis is illegal under federal law.

Back to top

For Healthcare Professionals

Scientific Name
Cannabis sativa
Clinical Summary

Cannabis sativa is an annual flowering herb native to East Asia, but is now cultivated around the world. Its uses as a source of industrial fiber, seed oil, and as a recreational agent date back thousands of years across cultures. It has also been employed in traditional medicine as an analgesic, hypnotic, and hallucinogenic, as a sedative, and for reducing inflammation. Preparations containing flowers (marijuana) and leaves; hashish derived from the resinous extract of the plant are consumed orally; by smoking in cigarettes, cigars, pipes, water pipes, or “blunts” (cannabis rolled in the tobacco-leaf wrapper from a cigar); or by vaporizing. Cannabis tinctures, teas, ointments, and oil-based extracts that can be mixed into food products are also popular. It is currently the most widely used illicit agent by more than 147 million people worldwide (1), and the common route of consumption is via inhalation. Because of the potential for high abuse and dependence, and its classification as a Schedule I agent by the Controlled Substances Act in 1970, cannabis use is a controversial subject in the US.

Pharmacologic investigations over the last few decades revealed cannabinoids (terpenoids) to be the active constituents. Delta-9-tetrahydrocannabinol (THC) is the chief psychoactive component whereas cannabidiol (CBD) is a major secondary non-psychoactive cannabinoid, and may modulate the effects of THC. It has antipsychotic, anticonvulsive, and anxiolytic effects. When co-administered, CBD was reported to mitigate the adverse psychotropic and cardiovascular effects associated with THC (2).

Small studies have evaluated cannabis for its utility in treating pain, symptoms of neurological disorders, AIDS and cancer.
A systematic review of 18 trials (766 subjects) reported significant relief from pain due to neuropathy, fibromyalgia, rheumatoid arthritis, and mixed chronic pain following cannabinoid use compared to placebo. The interventions included smoked cannabis, oromucosal extracts of cannabis-based medicine, synthetic THC agents dronabinol, nabilone (FDA approved), and a novel THC analogue (3). But a 4-year prospective study involving 1,514 patients with chronic non-cancer pain did not find evidence that cannabis use decreased pain severity or interference, or exerted an opioid-sparing effect (4).

In a Cochrane review of four trials involving 48 epileptic patients, short-term CBD use was reported to be well tolerated with no adverse effects, but limited evidence precluded definitive conclusions to be reached on efficacy (5). Newer randomized studies of patients with either Lennox-Gastaut syndrome or Dravet syndrome, both rare forms of epilepsy, reported effectiveness of Epidiolex, an oral CBD solution, for reducing the frequency of seizures (6). This is now an FDA-approved drug (7). Additionally, data indicate benefits of cannabinoids for treating spasticity and neuropathic pain in multiple sclerosis (MS) patients (8). The American Academy of Neurology issued a Summary of Systematic Reviews for Clinicians indicating that oral cannabis extract is effective in reducing patient-reported spasticity scores and central pain or painful spasms associated with MS (9).

Conclusions from a large, comprehensive review of 79 trials (6462 subjects) indicate low-quality evidence to address weight gain from HIV infection, sleep disorders, increasing appetite, and for Tourette syndrome, along with elevated risk of short-term adverse effects (10). The evidence for recommending cannabinoids to treat symptoms of dyskinesia, Parkinson’s and Huntington’s diseases, irritable bowel syndrome, and addiction has been deemed unavailable or insufficient (11).

In oncologic settings, preclinical findings from 34 studies suggest selective cytotoxic effects of cannabinoids against glioma cells (sparing normal brain cells) via apoptosis, toxicity, autophagy and necrosis (12). A single clinical trial of 9 patients with recurrent glioblastoma multiforme receiving chemotherapy did not find any benefit with intratumoral THC, but it was well tolerated (13). Data from another randomized study, involving 21 glioblastoma patients, in which oromucosal whole plant extract nabiximols (contains THC +CBD) was used, have yet to be published (14).

For symptom management, systematic reviews (10) (15) show that patients who used cannabis-based products experienced less chemo-induced nausea and vomiting compared to those on placebo group or on antiemetics. The differences were not statistically significant and adverse effects including “feeling high,” dizziness, sedation, and dysphoria were reported, resulting in a high dropout rate.  Noteworthy are the 2017 American Society of Clinical Oncology (ASCO) guidelines on antiemetics that recommend dronabinol and nabilone for nausea and vomiting, which is resistant to standard therapy (16).

Findings on effectiveness of cannabis against cancer pain are encouraging. Data from four trials indicate reductions in pain with orally administered THC and with nabiximols spray in advanced cancer patients (17). An earlier review concluded the evidence level of cannabinoids for alleviating cancer pain as moderate (10). Cannabis has also been investigated for its role in ameliorating cancer-related anorexia-cachexia syndrome (CACS), but neither cannabis extract nor THC were found effective in improving symptoms or quality of life in a randomized trial of patients with advanced cancer (18). Additional case reports suggest that dronabinol may be useful for managing persistent symptomatic paraneoplastic night sweats in cancer patients (19). In one patient with acute lymphoblastic leukemia, a cannabinoid resin extract was reported to affect dose-dependent disease control (20). In a randomized uncontrolled study, THC-containing medicinal cannabis was found to improve sleep, functional well-being, and quality of life in patients with high grade gliomas (67). However, a retrospective observational study showed that concomitant use of cannabis during immunotherapy with nivolumab was associated with reduction in tumor response rate in patients with advanced melanoma, non-small-cell lung cancer, and renal clear cell carcinoma. Progression-free survival and overall survival remained unaffected (21).

Although some data suggest potential benefits, cannabis remains a contentious issue because non-medical use is associated with high risk of addiction, especially when used from an early age (22) (23); dependence (24); adverse effects (25); and with withdrawal syndrome (irritability, sleeping difficulties, dysphoria, craving, and anxiety) (26) that makes cessation tough, eventually leading to relapse. Cannabis use was also reported to elevate the risk of creating false memories (62).

Recent studies suggest utility of nicotine patch in decreasing negative affect-related withdrawal symptoms in individuals with cannabis use disorder (63); and in patients with cannabis dependence, nabiximols combined with psychosocial interventions reduced cannabis use (58). However, an incentive-based intervention was ineffective in individuals with early psychosis and problematic cannabis use (59).

It is also important to note that synthetic cannabinoid drugs cause more serious adverse effects compared to natural cannabis, and include respiratory difficulties, hypertension, tachycardia, chest pain, muscle twitches, acute renal failure, anxiety, agitation, psychosis, suicidal ideation and cognitive impairment (27).

Despite the controversy surrounding cannabis use, California became the first state to legalize it for “medical use” in 1996. As of May 2021, it is available in 35 more states and the District of Columbia (DC) as a medicinal agent, with 16 states and DC also allowing recreational use. Current indications that qualify for medical cannabis use include cancer symptoms, non-cancer pain, glaucoma, AIDS, epilepsy, and MS. However, cannabis use remains illegal under federal law. Following a review of available scientific evidence, the Institute of Medicine (28), and the National Academies of Sciences, Engineering, and Medicine recommend that further research be done to develop a comprehensive understanding of the health effects of cannabis (11), which can inform medical cannabis policy. Barriers to research include regulatory issues that involve the FDA, Drug Enforcement Administration, National Institute on Drug Abuse, and Institutional Review Boards; procuring cannabis for studies; and methodological challenges of establishing an acceptable route of administration and standardized doses (29).

Purported Uses
  • Pain
  • Glaucoma
  • Chemo-induced nausea and vomiting
  • Mood Disorders
  • Sleep
  • Appetite stimulant
  • Multiple Sclerosis
  • Spasticity
  • Epilepsy
  • Cancer treatment
Mechanism of Action

Cannabinoids are the active constituents that mimic endogenous cannabinoids, and their activity is based on a receptor-mediated mechanism. THC exerts psychoactive and pain-relieving effects by acting as a partial agonist of cannabinoid receptors CB1 (predominantly expressed in the central nervous system) and CB2 (associated with the immune system). CB1 and CB2 are members of the G protein-coupled receptors (30), and are activated through inhibition of adenylate-cyclase. The activation in turn inhibits the release of neurotransmitters acetylcholine and glutamate, while indirectly affecting opioid and serotonin receptors, gamma-aminobutyric acid and N-methly-D-asparate (31). The antiemetic effect of nabilone is due to its ability to activate CB receptors in the brain, which mediate nausea and vomiting (32).

Mechanisms by which CBD exerts its effects include activation of the serotonin receptor 5-HT1A (33); inhibition of reuptake and/or metabolism of anandamide, an endocannabinoid; activation of transient receptor potential vanilloid (TRPV1) channels; inhibition of adenosine reuptake; agonism of PPAR-gamma receptors; by intracellular increase in calcium ions; as well as via anti-oxidative activity (34).

After inhalation of cannabis, THC is detectable in plasma within seconds, with peak plasma concentration achieved within 3-10 minutes. The bioavailability of THC varies and depends on the depth of inhalation, puff duration, and breath-hold. The systemic bioavailability is estimated to be ∼23-27% for heavy users; and 10-14% for occasional users. 
Following onset of smoking (cigarette containing 15.8 or 33.8 mg THC), the maximum THC plasma concentration (84.3 and 162.2 ng/mL) is attained at about 8 minutes and within 3-4 hours, falls rapidly to 1-4 ng/mL (35).
When compared to smoking and inhalation, systemic absorption following oral ingestion was slower, with maximum plasma concentration (4.4-11 ng/mL for 20 mg; and 2.7-6.3 ng/mL for 15 mg) of THC attained in 1-2 hours.  Substantial metabolism in the liver, via microsomal hydroxylation and oxidation catalyzed by enzymes of cytochrome P450 complex, likely lowers oral bioavailability of THC by 4-12%.
Much of the cannabis (80-90%) is excreted within 5 days in the form of hydroxylated and carboxylated metabolites (more than 65% of cannabis is excreted in the feces, with about 20% in urine). It is also important to note that residual THC levels have a half-life of 1.3 days in infrequent users compared to 5-13 days in frequent users (36).

Data on cannabidiol indicate the half-life to be between 1.4 and 10.9 h following oromucosal spray; 2–5 days following chronic oral administration; 24 h following intravenous administration; and 31 h following smoking. Bioavailability after smoking was 31%, but has yet to be determined with other routes. The maximum concentration is reached much faster following smoking and inhalation compared to oral and oromucosal routes. The Tmax has been reported to be achieved between 0 and 4 h (37).

Contraindications

Cannabis products should not be used by patients with psychiatric, cardiovascular, renal, or hepatic illnesses (38).

Adverse Reactions
  • Short-term adverse effects following use of medical cannabinoids include dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucination (10)
  • Chronic bronchitis in regular users of cannabis products compared to non-users (39)
  • Inhalation is associated with myocardial infarction, sudden cardiac death, cardiomyopathy, stroke, transient ischemic attack, and cannabis arteritis (40)
  • Cannabis use has been associated with increased risk of rare, but life-threatening cardiac dysrhythmia (64); as well as both acute coronary syndrome and chronic cardiovascular disease (65).
  • Long-term cannabis use was shown to be detrimental to functional connectivity in the developing brain (41)
  • Risk of addiction (22) (23)
  • Withdrawal syndrome (irritability, sleeping difficulties, dysphoria, craving, and anxiety) upon cessation (26)
  • Cannabis hyperemesis syndrome (CHS), characterized by cyclic attacks of nausea and vomiting in chronic cannabinoid users, has been attributed to two deaths (42). In another case series, four patients were reported to experience relief from CHS following administration of benzodiazepines (60).
  • Non-ischaemic cardiomyopathy and cardioembolism: In a recreational cannabis + tobacco smoker. He also developed gangrene in his left forearm as a result of left radial artery thrombosis. The patient was managed in the line of decompensated heart failure, with the right-hand gangrene requiring amputation (68).
  • Perioperative morbidity in elective spine surgery patients: A large retrospective analysis found cannabis abuse to be associated with increased perioperative morbidity among spine surgery patients (69).
Herb-Drug Interactions
  • Cytochrome P450 substrates: Smoking cannabis induces CYP1A2, with additive effects when smoked together with tobacco, and can affect the intracellular concentration of drugs metabolized by this enzyme (43)
  • Cytochrome P450 substrates: In vitro, CBD strongly inhibits CYP2C19 (44)and CYP2C9 (45). Clinical relevance is not known.
  • Immunotherapy (nivolumab): Combined use with cannabis was associated with a reduction in treatment response rates in patients with advanced melanoma, non-small-cell lung cancer, and renal clear cell carcinoma (observational study) (21) (46)
  • Warfarin: THC and CBD both elevate international normalized ratio (INR) levels (45) (47) (61)
  • Fluoxetine: Case reports of mania resulting from co-administration of cannabis (48)
  • Disulfiram: Delirium and hypomania resulting from co-administration with cannabis (49) (50)
  • Amphetamines, cocaine, atropine and sympathomimetic agents: Cardiotoxicity may occur with cannabis via additive hypertension and tachycardia (51) (52)
  • Sedatives or hypnotics: Sedation and significant pharmacodynamic interactions when taken with cannabis via potentiation of central effects (53)
  • P-glycoprotein substrates: CBD inhibits P-glycoprotein and may influence metabolism of certain drugs (54). Clinical relevance is not known.
  • Clobazam: CBD increased clobazam levels in epileptic children (55)
  • Buprenorphine: A retrospective study found that cannabis use decreased the formation of norbuprenorphine and elevated buprenorphine and norbuprenorphine levels in liver healthy individuals on opioid maintenance therapy substituted with buprenorphine. This interaction may lead to increased or altered opioid activity and risk of intoxication (66).
  • Citalopram/Escitalopram: CBD significantly elevated citalopram plasma concentrations in patients taking citalopram or escitalopram. But it is unclear whether this also increased SSRI-mediated adverse effects (70).
Dosage (OneMSK Only)
References
  1. WHO. Cannabis. https://www.who.int/substance_abuse/facts/cannabis/en/ Accessed July 16, 2020.
  2. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66(2):234-246.
  3. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. Nov 2011;72(5):735-744.
  4. Campbell G, Hall WD, Peacock A, et al. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health. Jul 2018;3(7):e341-e350.
  5. Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. Mar 5 2014(3):CD009270.
  6. O’Connell BK, Gloss D, Devinsky O. Cannabinoids in treatment-resistant epilepsy: A review. Epilepsy Behav. May 2017;70(Pt B):341-348.
  7. FDA US. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. 2018; https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm611046.htm Accessed July 16, 2020.
  8. Rice J, Cameron M. Cannabinoids for Treatment of MS Symptoms: State of the Evidence. Curr Neurol Neurosci Rep. Jun 19 2018;18(8):50.
  9. Neurology AAO. Efficacy and safety of the therapeutic use of medical marijuana (cannabis) in selected neurologic disorders. 2014; October 9, 2019.
  10. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. Jun 23-30 2015;313(24):2456-2473.
  11. Abrams DI. The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report. Eur J Intern Med. Mar 2018;49:7-11.
  12. Rocha FC, Dos Santos Junior JG, Stefano SC, da Silveira DX. Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas. J Neurooncol. Jan 2014;116(1):11-24.
  13. Guzman M, Duarte MJ, Blazquez C, et al. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. Jul 17 2006;95(2):197-203.
  14. Pharmaceuticals G. GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma. February 7, 2017; https://www.globenewswire.com/news-release/2017/02/07/914583/0/en/GW-Ph…. Accessed July 16, 2020.
  15. Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev. Nov 12 2015(11):CD009464.
  16. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. Oct 1 2017;35(28):3240-3261.
  17. Blake A, Wan BA, Malek L, et al. A selective review of medical cannabis in cancer pain management. Ann Palliat Med. Dec 2017;6(Suppl 2):S215-S222.
  18. Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol. Jul 20 2006;24(21):3394-3400.
  19. Carr C, Vertelney H, Fronk J, Trieu S. Dronabinol for the Treatment of Paraneoplastic Night Sweats in Cancer Patients: A Report of Five Cases. J Palliat Med. Feb 13 2019.
  20. Singh Y, Bali C. Cannabis extract treatment for terminal acute lymphoblastic leukemia with a Philadelphia chromosome mutation. Case Rep Oncol. Sep 2013;6(3):585-592.
  21. Taha T, Meiri D, Talhamy S, Wollner M, Peer A, Bar-Sela G. Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies. Oncologist. Jan 22 2019.
  22. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. Oct 17 2009;374(9698):1383-1391.
  23. Lopez-Quintero C, Perez de los Cobos J, Hasin DS, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. May 1 2011;115(1-2):120-130.
  24. Quality CFBHSA. National survey on drug use and health. 2013; https://www.samhsa.gov/data/sites/default/…/NSDUHmhfr2013/NSDUHmhfr2013.pdf Accessed July 16, 2020.
  25. Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. Jun 5 2014;370(23):2219-2227.
  26. Gorelick DA, Levin KH, Copersino ML, et al. Diagnostic criteria for cannabis withdrawal syndrome. Drug Alcohol Depend. Jun 1 2012;123(1-3):141-147.
  27. Cohen K, Weinstein AM. Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective. Front Public Health. 2018;6:162.
  28. Joy J, Watson SJJ, Benson JJ, eds. Marijuana and medicine: assessing the science base. Washington, DC: National Academy Press; 1999.
  29. National Academies of Sciences E, and Medicine, Health and Medicine Division BoPHaPHP, Marijuana CotHEo. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington (DC): National Academies Press (US); 2017.
  30. Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond). Apr 2006;30 Suppl 1:S13-18.
  31. Iversen L. Cannabis and the brain. Brain. Jun 2003;126(Pt 6):1252-1270.
  32. Davis MP. Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investig Drugs. Jan 2008;17(1):85-95.
  33. Lee JLC, Bertoglio LJ, Guimaraes FS, Stevenson CW. Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders. Br J Pharmacol. Oct 2017;174(19):3242-3256.
  34. McPartland JM, Duncan M, Di Marzo V, Pertwee RG. Are cannabidiol and Delta(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. Feb 2015;172(3):737-753.
  35. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol. Sep-Oct 1992;16(5):276-282.
  36. Sharma P, Murthy P, Bharath MM. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry. Fall 2012;7(4):149-156.
  37. Millar SA, Stone NL, Yates AS, O’Sullivan SE. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Front Pharmacol. 2018;9:1365.
  38. Administration TG. Australian Public Assessment Report for Nabiximols. . 2013;  https://www.tga.gov.au/sites/default/files/auspar-nabiximols-130927.pdf Accessed July 16, 2020.
  39. Tashkin DP. Effects of marijuana smoking on the lung. Ann Am Thorac Soc. Jun 2013;10(3):239-247.
  40. Thomas BF. Interactions of Cannabinoids With Biochemical Substrates. Subst Abuse. 2017;11:1178221817711418.
  41. Zalesky A, Solowij N, Yucel M, et al. Effect of long-term cannabis use on axonal fibre connectivity. Brain. Jul 2012;135(Pt 7):2245-2255.
  42. Nourbakhsh M, Miller A, Gofton J, Jones G, Adeagbo B. Cannabinoid Hyperemesis Syndrome: Reports of Fatal Cases. J Forensic Sci. Jan 2019;64(1):270-274.
  43. Anderson GD, Chan LN. Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products. Clin Pharmacokinet. Nov 2016;55(11):1353-1368.
  44. Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013;28(4):332-338.
  45. Yamaori S, Koeda K, Kushihara M, Hada Y, Yamamoto I, Watanabe K. Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. Drug Metab Pharmacokinet. 2012;27(3):294-300.
  46. Taha T, Talhamy S, Wollner M, Peer A, Bar-Sela G. The effect of cannabis use on tumor response to nivolumab in patients with advanced malignancies.  Annals of Oncology. 1 September 2017;28(suppl_5).
  47. Damkier P, Lassen D, Christensen MMH, Madsen KG, Hellfritzsch M, Pottegard A. Interaction between warfarin and cannabis. Basic Clin Pharmacol Toxicol. Jan 2019;124(1):28-31.
  48. Stoll AL, Cole JO, Lukas SE. A case of mania as a result of fluoxetine-marijuana interaction. J Clin Psychiatry. Jun 1991;52(6):280-281.
  49. Mackie J, Clark D. Cannabis toxic psychosis while on disulfiram. Br J Psychiatry. Mar 1994;164(3):421.
  50. Lacoursiere RB, Swatek R. Adverse interaction between disulfiram and marijuana: a case report. Am J Psychiatry. Feb 1983;140(2):243-244.
  51. Foltin RW, Fischman MW, Pedroso JJ, Pearlson GD. Marijuana and cocaine interactions in humans: cardiovascular consequences. Pharmacol Biochem Behav. Dec 1987;28(4):459-464.
  52. Benowitz NL, Jones RT. Prolonged delta-9-tetrahydrocannabinol ingestion. Effects of sympathomimetic amines and autonomic blockades. Clin Pharmacol Ther. Mar 1977;21(3):336-342.
  53. Arellano AL, Papaseit E, Romaguera A, Torrens M, Farre M. Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines. CNS Neurol Disord Drug Targets. 2017;16(5):554-566.
  54. Zhu HJ, Wang JS, Markowitz JS, et al. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J Pharmacol Exp Ther. May 2006;317(2):850-857.
  55. Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. Aug 2015;56(8):1246-1251.
  56. Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. May 2012;13(5):438-449.
  57. Duran M, Perez E, Abanades S, et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol. Nov 2010;70(5):656-663.
  58. Lintzeris N, Bhardwaj A, Mills L, et al. Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial.JAMA Intern Med. 2019 Jul 15. [Epub ahead of print]
  59. Johnson S, Rains LS, Marwaha S, et al. A contingency management intervention to reduce cannabis use and time to relapse in early psychosis: the CIRCLE RCT. Health Technol Assess. 2019 Aug;23(45):1-108.
  60. Kheifets M, Karniel E, Landa D, Vons SA, Meridor K, Charach G. Resolution of Cannabinoid Hyperemesis Syndrome with Benzodiazepines: A Case Series.Isr Med Assoc J. 2019 Jun;21(6):404-407.
  61. Hsu A, Painter NA. Probable Interaction Between Warfarin and Inhaled and Oral Administration of Cannabis. J Pharm Pract. 2019 Jul 18:897190019854958.
  62. Kloft L, Otgaar H, Blokland A, Monds LA, Toennes SW, Loftus EF, Ramaekers JG. Cannabis increases susceptibility to false memory. Proc Natl Acad Sci U S A. 2020 Mar 3;117(9):4585-4589.
  63. Gilbert DG, Rabinovich NE, McDaniel JT. Nicotine patch for cannabis withdrawal symptom relief: a randomized controlled trial. Psychopharmacology (Berl). 2020 May;237(5):1507-1519.
  64. Richards JR, Blohm E, Toles KA, et al. The association of cannabis use and cardiac dysrhythmias: a systematic review. Clin Toxicol (Phila). 2020 Apr 8:1-9.
  65. Richards JR, Bing ML, Moulin AK, et al. Cannabis use and acute coronary syndrome. Clin Toxicol (Phila). 2019 Oct;57(10):831-841.
  66. Vierke C, Marxen B, Boettcher M, Hiemke C, Havemann-Reinecke U. Buprenorphine-cannabis interaction in patients undergoing opioid maintenance therapy. Eur Arch Psychiatry Clin Neurosci. 2020 Jan 6.
  67. Schloss J, Lacey J, Sinclair J, et al. A Phase 2 Randomised Clinical Trial Assessing the Tolerability of Two Different Ratios of Medicinal Cannabis in Patients With High Grade Gliomas. Front Oncol. 2021 May 21;11:649555.
  68. Singh BO, Panda PK, Walia R. Recreational cannabis use causing non-ischaemic cardiomyopathy and cardioembolism in a young adult. BMJ Case Rep. 2021 Jun 1;14(6):e243193.
  69. Chiu RG, Patel S, Siddiqui N, Nunna RS, Mehta AI. Cannabis Abuse and Perioperative Complications Following Inpatient Spine Surgery in the United States. Spine (Phila Pa 1976). 2021 Jun 1;46(11):734-743.
  70. Anderson LL, Doohan PT, Oldfield L, et al. Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People. J Clin Psychopharmacol. 2021 Jun 11.
Back to top
Back to top
Email your questions and comments to [email protected].

Last Updated